 | ||
Tom SchirrisTom Schirris, CSBB PhD since October 2010 WP3: Model validation, refinement and application. AL3: Evaluation of off-target mitochondrial bioenergetic effects of pharmaceuticals. This action line aims to develop a model of the skeletal myoblasts and myotubes being able to give a sensitive prediction of mitochondrial toxicity. Effects of pharmaceuticals will be investigated on both human and mice myoblasts and myotubes using a wide range of methods present within the CSBB. This knowledge about off-target bioenergetic effects of pharmaceuticals will be used to validate the model developed in WP 1 and 2. These models will allow for a better understanding and prediction of off-target mitochondrial drug effects and the identification of sensitive biomarkers of drug-induced metabolic changes in muscle. This will contribute to better recognition of adverse bioenergetic effects in the process of drug development and to improve the safety of drug treatment by indentifying patients at risk. Contact details: | ||
